Bristol-Myers Squibb shareholders have approved the company’s proposed deal to buy Celgene. The approval comes after several activist shareholders tried to end the $74 billion acquisition of Celgene. The companies could still face hurdles before the deal is final. (STAT)

The FDA has warned the public not to use mobile health apps to diagnose concussions. The warning mentioned apps that claim to be able to detect brain injuries during sporting events and are marketed to coaches or parents. The warning is another setback for the mobile health app market. (Business Insider)

Here’s what the CDC could do to curb anti-vaxxer information on social media. Advisers to the CDC’s Committee on Immunization Practices said one problem is that the anti-vaxxers are more social media savvy and the “good guys” aren’t as organized. Some said CDC could fund more social media outreach about vaccines. (CNN)

Johnson & Johnson has received FDA approval for its bladder cancer drug. The treatment, branded as Balversa, is the first approved treatment for bladder cancer that targets a genetic alteration known as FGFR3 or FGFR2. (Reuters)

Make sure your agency is counted among the best in pharma and healthcare marketing. Tomorrow is the deadline to submit questionnaires for MM&M‘s 2019 Agency Issue, the most comprehensive annual report on the pharma marketing universe.